What patent(s) cover Beyfortus (nirsevimab)?
Beyfortus is the brand name for nirsevimab, an antibody used in infants to help prevent Respiratory Syncytial Virus (RSV). Which specific patents cover Beyfortus depends on the country/region (for example, the US vs. Europe) and on whether the patent protection covers the active ingredient, its manufacturing, or related formulations/uses. The provided information does not include the patent numbers or jurisdictions tied to Beyfortus.
When do Beyfortus patents expire?
Patent expiry dates for Beyfortus are determined by the filing dates of the relevant patents and local rules for term adjustments/extended protection. Without the specific patent list and jurisdiction, it’s not possible to state an expiry timeline accurately.
Is Beyfortus protected by exclusivity beyond patents?
Beyond patents, regulators can grant regulatory or marketing exclusivity (which can extend market protection even after certain patent claims expire). The exact type and duration of any exclusivity for Beyfortus depends on the jurisdiction and approval history, which is not included in the provided material.
Are biosimilars or competitors coming before patent expiry?
Whether competitors can enter before specific patent expiry depends on:
- which patents are still enforceable,
- whether a competitor can launch with a “non-infringing” product, and
- local legal pathways (such as patent challenges or regulatory exclusivity rules).
No patent status details are provided here.
What information do I need to answer precisely?
If you share either of the following, I can help pinpoint the patents and explain the protection landscape:
- the country/region you care about (US, UK, EU, etc.), and
- any patent numbers you’ve seen (or the link/document you’re using).
If you’re trying to look it up yourself, where to search
To find Beyfortus-related patents, people typically use:
- Google Patents (search by “nirsevimab” or “Beyfortus”),
- national patent office databases for the relevant jurisdiction, and
- regulatory/authorization sites that sometimes link to protected product information.
Sources: none provided.